Document is current
Any future updates will be listed below
-
Authors
Ginzac, Angeline https://orcid.org/0000-0002-5614-0876
Dupic, Guillaume
Brun, Lucie
Molnar, Ioana https://orcid.org/0000-0001-5114-2648
Casile, Mélanie
Durando, Xavier https://orcid.org/0000-0001-6035-3172
Verrelle, Pierre
Lemaire, Jean-Jacques
Khalil, Toufic
Biau, Julian https://orcid.org/0000-0002-1570-4487
-
Funding
Funding for this research was provided by:
Direction Générale de l’offre de Soins (PHRCI-19-070)
- License Information
-
More Information
Article History
Received: 29 March 2021
Accepted: 15 July 2021
First Online: 28 July 2021
Declarations
:
: The study protocol and its amendments obtained approval from the French Ethics Committee (Comité de Protection des Personnes Sud-Ouest et Outre-Mer IV) and from the French National Agency for the Safety of Medicines and Health Products (ANSM) (N°ID RCB 2020-A0043–36) in July 2020.The study is conducted in accordance with the Helsinki Declaration, the Good Clinical Practice (GCP) guidelines of the International Conference on Harmonisation (ICH–E6, 17/07/96), General Data Protection Regulation (GDPR) and local regulatory requirements. Written informed consent will be obtained from each patient by the investigator before any study-related assessment starts.
: Not applicable.
: The authors declare that they have no competing interests.
